Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2013 4
2014 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bernabe p (92 results)?
Twenty years of treatment with Beriate P.
Brackmann HH. Brackmann HH. Thromb Res. 2014 Nov;134 Suppl 1:S1-3. doi: 10.1016/j.thromres.2013.10.011. Epub 2013 Dec 21. Thromb Res. 2014. PMID: 24360930 No abstract available.
The history of haemophilia - a short review.
Schramm W. Schramm W. Thromb Res. 2014 Nov;134 Suppl 1:S4-9. doi: 10.1016/j.thromres.2013.10.020. Epub 2014 Feb 7. Thromb Res. 2014. PMID: 24513149 Review.
The availability of pasteurized, and therefore virus-safe, plasma-derived, clotting factor concentrates, such as Haemate P() and Beriate() P in Germany and other countries, dramatically improved the quality of life and life expectancy of haemophilia patients. ...
The availability of pasteurized, and therefore virus-safe, plasma-derived, clotting factor concentrates, such as Haemate P() and Beriate
Beriate P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.
Klamroth R, Holzhauer S, Zimmermann R, Heller C, Kurnik K; Beriate® Pharmacovigilance Group. Klamroth R, et al. Thromb Res. 2014 Nov;134 Suppl 1:S16-21. doi: 10.1016/j.thromres.2013.10.014. Epub 2014 Jan 10. Thromb Res. 2014. PMID: 24418255
BACKGROUND: The German Beriate() P pharmacovigilance study started in 2003 and is planned to run until December 2013. MATERIALS AND METHODS: This analysis included data from 84 haemophilia A patients treated with the high-purity, plasma-derived coagulation factor VI …
BACKGROUND: The German Beriate() P pharmacovigilance study started in 2003 and is planned to run until December 2013. MATERIAL …
Pathogen safety of Beriate®.
Gröner A. Gröner A. Thromb Res. 2014 Nov;134 Suppl 1:S10-5. doi: 10.1016/j.thromres.2013.10.013. Epub 2014 Apr 13. Thromb Res. 2014. PMID: 24726555 Review.
To ensure the pathogen safety of the plasma-derived FVIII concentrate, Beriate() (formerly Beriate() P), donors of blood/plasma are carefully selected and all donations are screened for hepatitis B virus surface antigen (HBsAg), antibodies against HIV types 1 and 2 …
To ensure the pathogen safety of the plasma-derived FVIII concentrate, Beriate() (formerly Beriate() P), donors of blood/plasm …
Beriate-P study.
Gringeri A. Gringeri A. Ann Hematol. 1994;68 Suppl 3:S53-4. doi: 10.1007/BF01774534. Ann Hematol. 1994. PMID: 7910041 Clinical Trial. No abstract available.
Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate P) in patients with haemophilia A.
Klamroth R, Gottstein S, Orlovic M, Heinrichs C. Klamroth R, et al. Thromb Res. 2014 Nov;134 Suppl 1:S38-42. doi: 10.1016/j.thromres.2013.10.015. Epub 2013 Nov 17. Thromb Res. 2014. PMID: 24256767 Free PMC article.
MATERIALS AND METHODS: We analysed the efficacy and safety of Beriate() P in the clinical setting from 1996 to 2005 with a focus on surgical patients. ...CONCLUSION: Beriate() P has an excellent efficacy and safety profile. Many patients who were initi …
MATERIALS AND METHODS: We analysed the efficacy and safety of Beriate() P in the clinical setting from 1996 to 2005 with a foc …
Prospective study of continuous infusion with Beriate P in patients with severe haemophilia A undergoing surgery - a subgroup analysis.
Auerswald G, Bade A, Johne J, Haubold K, Overberg D, Masurat S, Moorthi C. Auerswald G, et al. Thromb Res. 2014 Nov;134 Suppl 1:S43-7. doi: 10.1016/j.thromres.2013.10.009. Epub 2013 Dec 21. Thromb Res. 2014. PMID: 24360932
We conducted a prospective subgroup analysis to investigate if CI of the high-purity, pasteurized, plasma-derived FVIII concentrate Beriate() P during surgery increases the risk of inhibitor formation. ...CONCLUSION: Beriate() P was efficacious, safe, …
We conducted a prospective subgroup analysis to investigate if CI of the high-purity, pasteurized, plasma-derived FVIII concentrate Beria
Challenges for new haemophilia products from a manufacturer's perspective.
Schulte S. Schulte S. Thromb Res. 2014 Nov;134 Suppl 1:S72-6. doi: 10.1016/j.thromres.2013.10.021. Epub 2013 Dec 21. Thromb Res. 2014. PMID: 24360931 Review.
This article describes some of the challenges that were experienced by the manufacturer during the development of the high-purity, plasma-derived factor VIII concentrate, Beriate P, which, after implementation of a nanofiltration step in its manufacture, is now desi …
This article describes some of the challenges that were experienced by the manufacturer during the development of the high-purity, plasma-de …
Treatment of haemophilia patients in East Germany prior to and after reunification in 1990.
Lenk H. Lenk H. Thromb Res. 2014 Nov;134 Suppl 1:S57-60. doi: 10.1016/j.thromres.2013.10.018. Epub 2014 Apr 16. Thromb Res. 2014. PMID: 24745720 Review.
Reunification coincided with the availability of virus-safe, high-purity plasma-derived factor VIII concentrates (e.g. Beriate() P), which changed the outlook for patients in terms of convenience, tolerability, and virus safety; and these new products quickly became …
Reunification coincided with the availability of virus-safe, high-purity plasma-derived factor VIII concentrates (e.g. Beriate() P